Uncategorized
Extension study highlights long-term outcomes of aflibercept in DME
Two-year results of the ENDURANCE phase 4 extension study, evaluating the long-term efficacy and safety of intravitreal aflibercept for the treatment of diabetic macular edema in subjects who completed the VISTA DME trial, showed stability of visual acuity gain and substantial reduction in the average number of injections required. The study enrolled, on a voluntary basis, 60 patients among those included in the 3-year VISTA trial, 54 of whom completed week 104. After the monthly administration of Eylea (aflibercept, Regeneron) in the VISTA trial, patients in the ENDURANCE trial were (Read more...)